Compare Stocks: ANNX, QURE, CLDX, and IMNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.94	$5.26	$2.32 ▼ $7.18	$746.95M	1.21	2.54 million shs	3.94 million shs
CLDX Celldex Therapeutics	$36.90	$39.16	$22.10 ▼ $45.14	$2.90B	0.84	659,928 shs	1.03 million shs
IMNM Immunome	$24.67	$25.33	$8.93 ▼ $30.06	$2.80B	2.13	982,553 shs	692,557 shs
QURE uniQure	$44.51	$44.36	$8.73 ▼ $71.50	$3.09B	0.94	1.11 million shs	1.24 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-19.10%	-25.52%	-15.09%	+62.81%
CLDX Celldex Therapeutics	0.00%	-7.01%	-12.04%	+14.88%	+50.92%
IMNM Immunome	0.00%	-7.81%	-9.30%	+36.52%	+167.86%
QURE uniQure	0.00%	+0.02%	-8.45%	+59.71%	+169.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.94	$5.26	$2.32 ▼ $7.18	$746.95M	1.21	2.54 million shs	3.94 million shs
CLDX Celldex Therapeutics	$36.90	$39.16	$22.10 ▼ $45.14	$2.90B	0.84	659,928 shs	1.03 million shs
IMNM Immunome	$24.67	$25.33	$8.93 ▼ $30.06	$2.80B	2.13	982,553 shs	692,557 shs
QURE uniQure	$44.51	$44.36	$8.73 ▼ $71.50	$3.09B	0.94	1.11 million shs	1.24 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-19.10%	-25.52%	-15.09%	+62.81%
CLDX Celldex Therapeutics	0.00%	-7.01%	-12.04%	+14.88%	+50.92%
IMNM Immunome	0.00%	-7.81%	-9.30%	+36.52%	+167.86%
QURE uniQure	0.00%	+0.02%	-8.45%	+59.71%	+169.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	284.34% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.42	52.89% Upside
IMNM Immunome	2.85	Moderate Buy	$34.64	40.40% Upside
QURE uniQure	2.76	Moderate Buy	$65.00	46.03% Upside

Current Analyst Ratings Breakdown

Latest ANNX, QURE, CLDX, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$46.00 ➝ $50.00
9/10/2026	IMNM Immunome	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/2/2026	QURE uniQure	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/12/2026	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$31.00 ➝ $35.00
8/12/2026	IMNM Immunome	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
7/30/2026	QURE uniQure	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$65.00 ➝ $60.00
7/30/2026	QURE uniQure	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$60.00 ➝ $75.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CLDX Celldex Therapeutics	$1.54M	1,881.66	N/A	N/A	$7.93 per share	4.65
IMNM Immunome	$6.94M	403.75	N/A	N/A	$5.75 per share	4.29
QURE uniQure	$16.10M	191.78	N/A	N/A	$3.19 per share	13.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
IMNM Immunome	-$212.39M	-$2.53	N/A	N/A	N/A	N/A	-50.56%	-46.93%	11/5/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)

Latest ANNX, QURE, CLDX, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/11/2026	Q2 2026	IMNM Immunome	-$0.5138	-$0.65	-$0.1362	-$0.65	$0.17 million	N/A
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
CLDX Celldex Therapeutics	N/A	11.82	11.82
IMNM Immunome	N/A	15.08	15.08
QURE uniQure	0.15	10.01	10.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
CLDX Celldex Therapeutics	N/A
IMNM Immunome	44.58%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
CLDX Celldex Therapeutics	5.20%
IMNM Immunome	7.21%
QURE uniQure	4.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
IMNM Immunome	177	113.58 million	105.39 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable

ANNX, QURE, CLDX, and IMNM Headlines

Recent News About These Companies

FDA expands Bayer lung cancer drug approval

September 10, 2026 | statnews.comS

What to expect from UniQure’s upcoming Huntington’s gene therapy readout

September 10, 2026 | statnews.comS

Squarepoint Ops LLC Has $12.91 Million Stock Holdings in uniQure N.V. $QURE

September 10, 2026 | marketbeat.com

uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application?

September 8, 2026 | insidermonkey.com

uniQure N.V. $QURE Shares Sold by Readystate Asset Management LP

September 7, 2026 | marketbeat.com

QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy

September 6, 2026 | ad-hoc-news.deA

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 5, 2026 | investorplace.com

Wall Street Zen Downgrades uniQure (NASDAQ:QURE) to Sell

September 5, 2026 | americanbankingnews.com

uniQure (NASDAQ:QURE) Lowered to Sell Rating by Wall Street Zen

September 5, 2026 | marketbeat.com

uniQure submits ifezuntirgene inilparvovec BLA to US FDA to treat Huntington’s disease

September 4, 2026 | pharmabiz.comP

uniQure (NASDAQ:QURE) Shares Gap Up - Here's Why

September 4, 2026 | americanbankingnews.com

uniQure (NASDAQ:QURE) Coverage Initiated at William Blair

September 4, 2026 | americanbankingnews.com

uniQure files for US and UK approval for AMT-130 in Huntington’s disease

September 3, 2026 | thepharmaletter.comT

uniQure (NASDAQ:QURE) Trading Down 4.4% - Here's Why

September 3, 2026 | marketbeat.com

QURE Submits Application for Gene Therapy for Huntington's Disease

September 3, 2026 | zacks.com

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

September 3, 2026 | investorplace.com

UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

September 2, 2026 | biopharmadive.comB

UniQure Submits Biologics License Application For AMT-130 In Huntington's Disease; Stock Up

September 2, 2026 | rttnews.com

Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more

September 2, 2026 | statnews.comS

uniQure Submits BLA for AMT-130 in Huntington's Disease

September 2, 2026 | finance.yahoo.com

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

September 2, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, QURE, CLDX, and IMNM Company Descriptions

Annexon NASDAQ:ANNX

$3.94 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.91 -0.03 (-0.76%)

As of 06:18 AM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Celldex Therapeutics NASDAQ:CLDX

$36.90 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$37.13 +0.23 (+0.63%)

As of 06:18 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Immunome NASDAQ:IMNM

$24.67 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$24.50 -0.17 (-0.69%)

As of 06:25 AM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

uniQure NASDAQ:QURE

$44.51 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$44.60 +0.09 (+0.20%)

As of 05:25 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, QURE, CLDX, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, QURE, CLDX, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, QURE, CLDX, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, QURE, CLDX, and IMNM Company Descriptions

Annexon NASDAQ:ANNX

Celldex Therapeutics NASDAQ:CLDX

Immunome NASDAQ:IMNM

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, QURE, CLDX, and IMNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, QURE, CLDX, and IMNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, QURE, CLDX, and IMNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, QURE, CLDX, and IMNM Company Descriptions

Annexon NASDAQ:ANNX

Celldex Therapeutics NASDAQ:CLDX

Immunome NASDAQ:IMNM

uniQure NASDAQ:QURE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools